EVAX (EVAX) Stock Price & Analysis
EVAX (EVAX) fell 2.95% to USD 2.96 as of July 25, 2026 at 10:03 UTC, according to Nexqual real-time market data.
EVAX last closed at USD 3.05; the session ranged USD 2.93–3.09 on volume of 3,271 shares. Market capitalization is $24.69M, with a 52-week range of USD 2.45–12.15 (NCM). Source: Nexqual, July 25, 2026 at 10:03 UTC.
Key Statistics (as of July 25, 2026 at 10:03 UTC)
| Price | USD 2.96 |
|---|---|
| Change | ▼ 2.95% (down) |
| Previous Close | USD 3.05 |
| Open | USD 3.09 |
| Day Range | USD 2.93 – 3.09 |
| 52-Week Range | USD 2.45 – 12.15 |
| Volume | 3,271 shares |
| Market Cap | $24.69M |
| Exchange | NCM |
Technical Analysis (EVAX)
Nexqual's technical model rates EVAX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 10:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.15 (neutral) |
| vs SMA50 | Below (USD 3.5) |
| MACD | -0.14 (negative) |
Analyst Ratings (EVAX)
Wall Street analysts rate EVAX "None" based on 4 analysts, with a mean price target of USD 11.25 (range USD 9–16), per Nexqual as of July 25, 2026 at 10:03 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 11.25 |
| High Target | USD 16 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (EVAX)
| EPS Estimate | USD -0.01 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.01 vs est -0.01 ▲ beat |
| 2025-12-31 | USD -0.01 vs est -0.01 ▲ beat |
| 2025-09-30 | USD 0.01 vs est -0.01 ▲ beat |
| 2025-06-30 | USD -1 vs est -0.58 ▼ miss |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
Financials & Fundamentals (EVAX)
| Total Revenue | $7.53M |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -122.01% |
| Profit Margin | -129.60% |
| ROE | -82.93% |
| Total Cash | $18.44M |
| Total Debt | $0 |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
Financial Health Score (EVAX)
Nexqual rates EVAX's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 10:03 UTC.
| Growth | Strong — Revenue +125% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $18M cash, no debt |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -83%, ROA -23.5% |
Ownership (EVAX)
| Insider Ownership | +17.47% |
|---|---|
| Institutional Ownership | +9.43% |
| Shares Outstanding | 8.34M |
| Float | 5.68M |
| Short % of Float | +0.30% |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
Leadership (EVAX)
EVAX is led by Helen Katrina Tayton-Martin (age 58), Chief Executive Officer, per Nexqual as of July 25, 2026 at 10:03 UTC.
| Chief Executive Officer | Helen Katrina Tayton-Martin (age 58) |
|---|---|
| Chief Financial Officer | Thomas Frederik Schmidt M.Sc. (age 54) |
| Chief Scientific Officer & COO | Birgitte Rono (age 48) |
| Vice President of Clinical Development | Benjamin Ole Wolthers |
Major Backers & Investors (EVAX)
Notable institutional backers of EVAX include Merck & Co., Inc., Ikarian Capital, LLC, Rathbones Group PLC, according to Nexqual as of July 25, 2026 at 10:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Merck & Co., Inc. | 14.56% |
| Ikarian Capital, LLC | 0.9% |
| Rathbones Group PLC | 0.55% |
| Renaissance Technologies | 0.47% |
| Annis Gardner Whiting Capital Advisors, LLC | 0.36% |
| Rhumbline Advisers | 0.26% |
| Xtx Topco Ltd | 0.26% |
| Stonepine Capital Management, LLC | 0.24% |
Source: Nexqual, July 25, 2026 at 10:03 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABVC | ABVC Biopharma, Inc. | USD 1.15 | ▼ 2.54% |
| RNXT | RenovoRx, Inc. | USD 0.87 | ▼ 0.08% |
| RNAZ | TransCode Therapeutics, Inc. | USD 5.93 | ▼ 29.4% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
| BBLG | Bone Biologics Corp | USD 1.07 | ▼ 2.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:03 UTC. This page is informational and not investment advice.